Coya Therapeutics' COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer's Disease

The open-label study evaluated the safety and tolerability, biological activity, blood biomarkers and preliminary efficacy of COYA 301 in 8 patients with Alzheimer’s disease . The... | May 16, 2023

Related Keywords

United States ,Houston ,Texas ,Americans ,Stanley Appel ,Adrian Hepner ,Alzheimer Association ,Centers For Disease ,Nasdaq ,Coya Therapeutics Inc ,Coya Therapeutics ,Keystone Conference ,New Biology Guiding ,Next Generation ,Therapeutic Development ,Houston Methodist ,Scientific Advisory Board ,Chief Medical Officer ,Disease Control ,Nc Stock Exchange ,News ,Information ,Press Release ,The ,Study ,Revaluated ,Safety ,End ,Biological ,Flood ,Biomarkers ,Reliminary ,Efficacy ,F ,Hoya ,01 ,N , ,Patients ,Ith ,Isease Coya Us22407b1089 ,